API receives a NIH grant for their second pre-clinical Alzheimer’s disease trial

On September 18, 2013, the Alzheimer's Prevention Initiative received a NIH grant for their second trial of an anti-amyloid treatment to prevent Alzheimer’s disease.
09/18/2013

On September 18, 2013, the Alzheimer's Prevention Initiative (API) received a NIH grant for their second trial of an anti-amyloid treatment to prevent Alzheimer’s disease. Expected to begin in 2015, the trial will test a treatment drug intended to attack amyloid plaques (a protein that accumulates in the brains of those with Alzheimer’s disease). The trial will be conducted in 650 cognitively normal individuals between the ages of 60 to 75 who have no symptoms of the disease, but do have two copies of the APOE4 gene known to greatly increase the risk of getting Alzheimer’s disease. Researchers anticipate that the drug could help delay memory or cognitive decline over five years. Dr. Scott Roberts, will serve on the API trial's expert committee on genetic testing and risk disclosure.

Click here to read the New York Times article about this NIH grant announcement.